MB
RARE icon

MPM BioImpact’s Ultragenyx Pharmaceutical RARE Stock Holding History

MPM BioImpact’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.4M Buy
+1,418,215
New +$35.2M 2.89% 12
2025
Q4 		– Sell
-395,700
Closed -$11.9M – 45
2025
Q3 		$11.9M Hold
395,700
– – 1.95% 25
2025
Q2 		$14.4M Sell
395,700
-2,745
-0.7% -$99K 2.49% 16
2025
Q1 		$14.4M Buy
398,445
+7,427
+2% +$309K 2.48% 16
2024
Q4 		$16.5M Buy
391,018
+61,285
+19% +$3.04M 2.34% 17
2024
Q3 		$18.3M Sell
329,733
-50,819
-13% -$2.59M 2.75% 11
2024
Q2 		$15.6M Buy
380,552
+134,962
+55% +$5.76M 2.43% 10
2024
Q1 		$11.5M Buy
+245,590
New +$11.6M 1.84% 19

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

MPM BioImpact's RARE Position: Q2 2026 in Review

MPM BioImpact opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 1,418,215 shares worth $47.4M. The stake represents 2.89% of the portfolio and ranks #12 among its holdings. This is a return to the name: MPM BioImpact previously reported a position in RARE as recently as Q3 2025.

MPM BioImpact first reported a position in RARE in Q1 2024 and has held it in 8 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • MPM BioImpact held 1,418,215 shares of Ultragenyx Pharmaceutical worth $47.4M as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new MPM BioImpact position in Q2 2026.
  • Ultragenyx Pharmaceutical made up 2.89% of MPM BioImpact's portfolio in Q2 2026, its #12 holding.
  • MPM BioImpact first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 8 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.